Africa offers fewer competing trials, good patient retention rates, patient populations eager to participate in trials providing access to scarce treatment and a generally favorable exchange rate versus major currencies, all resulting in cost savings of 25 percent – 30 percent.
Johannesburg, South Africa, provides an ideal base for Kendle’s Africa operations due to its modern infrastructure and relatively well-developed financial, legal, communications, transportation and energy systems. Experience in HIV/AIDS, tuberculosis, malaria and rotavirus are just some of the areas of therapeutic interest that make Kendle in Africa an attractive proposition for our customers.